Triazole

ADAMA Launches New Cereal Fungicide Avastel® for Superior Disease Control and Long-lasting Protection

Retrieved on: 
Lundi, avril 22, 2024
Active ingredient, TEL, Weather, Wheat, Triticale, Farmer, SDHI, Disease, Triazole, Pressure, DMI, Agriculture

Avastel® has powerful curative and long-term preventive effects against disease, resulting in a stronger flag leaf which is crucial for maximizing yields.

Key Points: 
  • Avastel® has powerful curative and long-term preventive effects against disease, resulting in a stronger flag leaf which is crucial for maximizing yields.
  • "At ADAMA, we invested in developing Avastel®, a breakthrough fungicide that contains two best-in-class Active Ingredients as well as our innovative Formulation Technology.
  • Avastel® is a broad label fungicide that is suitable for use in crops such as wheat, barley, rye, and triticale.
  • It is part of ADAMA's new European cereal fungicide portfolio which began rolling out in 2023.

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Patient, Liver, Lennox–Gastaut syndrome, Medical Subject Headings, Fungal infection, Marketing, Triazole, INN, Fatigue, Allergy, ATC, International, Headache, Disease, Ageing, Language, Blood, Sodium, Brain, Profile, Seizure, Dizziness, Water, European Medicines Agency, Learning disability, Food, Tablet, Select, Human, Anatomy, Somnolence, Vomiting, IIA, Medical device

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Retrieved on: 
Mercredi, octobre 11, 2023
Hemorrhagic cystitis, Male, Urine, Physician, NYSE, Internal medicine, Doctor of Philosophy, Division, Aspergillosis, LNC, MD, Fungal infection, Infection, University, Diabetes, Expanded access, Fluconazole, Roflumilast, Heart failure, Triazole, Kidney disease, Moyamoya disease, Patient, Candida krusei, Pharmaceutical industry, Raid on Matina

This patient was treated under Matinas’ Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.

Key Points: 
  • This patient was treated under Matinas’ Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
  • “We are thrilled with the positive clinical impact MAT2203 had on this extremely ill patient with limited treatment options,” said Dr. Miceli.
  • Treatment with MAT2203 led to complete resolution of his symptoms and improvement of his kidney function to baseline.
  • We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections.”
    MAT2203 is not yet licensed or approved anywhere globally.

Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Lundi, mai 29, 2023
Biotechnology, Pharmaceutical, Health, Molecule, Amphotericin B, Fungal infection, Risk factor, Imidazole, Prevalence, Diabetes, HIV, Blastomycosis, Posaconazole, Infection, Candidiasis, Overalls, Isavuconazonium, Ageing, Mucormycosis, Merck & Co., Polyene, Fungemia, CDC, Incidence, AR, Patient, Developed country, ROW, Growth, Mortality, Merck, Immunodeficiency, Immunosuppression, Cryptococcus, Pfizer, Triazole, Pharmaceutical industry, Vaccine, Voriconazole, Echinocandin, Aspergillosis, Azole, Fluconazole

However, there are also antibody molecules in early preclinical development, which are currently not on the market.

Key Points: 
  • However, there are also antibody molecules in early preclinical development, which are currently not on the market.
  • The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
  • By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
  • The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Retrieved on: 
Mardi, décembre 6, 2022
Asthma, Private equity, Pulmonology, United, Triazole, Mortality, Cystic fibrosis, Incidence, Series, Aspergillosis, Do Meu Jeito, Oxygen toxicity, Chronic pulmonary aspergillosis, Doctor of Philosophy, Critical care, Cystic Fibrosis Foundation, MD, Azole, Chronic obstructive pulmonary disease, Disease, Immunodeficiency, IP Group, Lung, Allergic bronchopulmonary aspergillosis, Growth, IPA, Investment, Risk, Respiratory disease, Patient, Pharmaceutical industry, Pulmocide, Aspergillus

Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.

Key Points: 
  • Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.
  • Jeito’s further investment in Pulmocide demonstrates our commitment to support the most innovative biopharmaceutical companies and accelerate the development of much-needed treatments for patients.
  • Jeito Capital has €534 million under management and a rapidly growing portfolio of investments.
  • A late-stage clinical program has been initiated to support registration in patients who have failed prior therapy for IPA.

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

Retrieved on: 
Jeudi, mai 27, 2021
Aspergillosis, Azole, Triazole

Existing investors SV Health Investors, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation JJDC, Inc., and Longwood Fund also participated.

Key Points: 
  • Existing investors SV Health Investors, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation JJDC, Inc., and Longwood Fund also participated.
  • Proceeds from the financing will primarily be used to advance the Companys lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.
  • PC945 is a potent, novel triazole antifungal that has been specifically designed for use as an inhaled therapy.
  • The PC945 registration program is expected to begin recruiting patients later this year.

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

Retrieved on: 
Jeudi, mai 27, 2021
Aspergillosis, Azole, Triazole

Existing investors SV Health Investors, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation JJDC, Inc., and Longwood Fund also participated.

Key Points: 
  • Existing investors SV Health Investors, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation JJDC, Inc., and Longwood Fund also participated.
  • Proceeds from the financing will primarily be used to advance the Companys lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.
  • PC945 is a potent, novel triazole antifungal that has been specifically designed for use as an inhaled therapy.
  • The PC945 registration program is expected to begin recruiting patients later this year.